Further, studies have shown that ER-stressed inhibitors reduce IL-5 production in Th-2 cells (naïve CD4+ T cells) [125], which inhibit colon and pancreatic cancer growth by promoting antitumorigenic responses from macrophages and eosinophils [80]. The gene discussed is IL5; the disease is familial pancreatic carcinoma.